Oral treatments for B-CLL, such as the BTK inhibitor ibrutinib and the BCL-2 inhibitor venetoclax, often in combination with the ADCC-inducing therapies obinutuzumab or rituximab, have demonstrated good clinical responses in first-line treatment of patients with B-CLL. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.